Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Fixed drug eruption due to methaqualone.

L Slazinski, D W Knox

    Archives of Dermatology
    |August 1, 1984
    PubMed
    Summary

    Fixed drug eruptions from methaqualone are rarely reported but may be common. Patient reluctance to admit use and physician unawareness of methaqualone abuse and its skin issues contribute to underreporting.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Cutaneous candidosis as a complication of facial dermabrasion.

    The Journal of dermatologic surgery and oncology·1984
    Same author

    Basal cell carcinoma in a man with acquired immunodeficiency syndrome.

    Journal of the American Academy of Dermatology·1984
    Same author

    Topical squaric acid dibutylester therapy for alopecia areata.

    Cutis·1982
    Same author

    Herpes gestationis associated with choriocarcinoma.

    Archives of dermatology·1982
    Same author

    Photorepair of pyrimidine dimers in human skin in vivo.

    Photochemistry and photobiology·1981
    Same author

    Excision repair of UV-induced pyrimidine dimers in human skin in vivo.

    The Journal of investigative dermatology·1981

    Area of Science:

    • Dermatology
    • Pharmacology
    • Toxicology

    Background:

    • Methaqualone, introduced in 1963, is a sedative-hypnotic drug.
    • Fixed drug eruption (FDE) is a specific type of adverse cutaneous drug reaction.
    • Previous reports of FDE due to methaqualone are scarce.

    Observation:

    • Three cases of fixed drug eruption attributed to methaqualone were observed over a two-year period.
    • The patients presented with characteristic recurrent skin lesions upon re-exposure to methaqualone.
    • These cases highlight a potential under-recognized association between methaqualone and FDE.

    Findings:

    • The frequency of dermatologic reactions, specifically FDE, from methaqualone may be underestimated.
    • Patient non-disclosure of methaqualone use or abuse can obscure diagnosis.
    • Lack of physician awareness regarding methaqualone abuse and its cutaneous manifestations contributes to underdiagnosis.

    Implications:

    • Increased clinical suspicion for FDE in patients using or abusing methaqualone is warranted.
    • Physicians should be educated on the potential for methaqualone-induced cutaneous reactions.
    • Further research is needed to determine the true prevalence of methaqualone-related FDE.

    Related Experiment Videos